Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is frequently used to mobilize CD34+ cells in healthy donors and patient with malignant diseases prior to peripheral blood stem cell (PBSC) harvest. To analyze the effects of rhG-CSF on morphology and genotype of white blood cells, a novel multiparametric cell scanning system that combines morphologic, immune and genotypic analyses of the same cells was used. We report here that tetraploid myeloid cells are present in the peripheral blood of donors treated with rhG-CSF. The tetraploidy was detected in up to 0.6% of differentiated myeloid cells and all observed CD34+ cells were diploid. Thus, short treatment with rhG-CSF of PBSC donors induces numerical chromosomal alterations in a small subset of mature myeloid cells.
stem cell harvest; peripheral stem cell transplantation Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that regulates the production, proliferation, differentiation and maturation of myeloid progenitors. It has been widely used for treatment of neutropenia. 1 Short treatment with recombinant human GCSF (rhG-CSF) also mobilizes CD34+ cells into the peripheral blood. 2 This observation has led to the common practice of treating donors of peripheral blood stem cells (PBSC) for transplantation with rhG-CSF for several days before harvest. 3 Less often rhG-CSF is given to healthy donors of granulocyte transfusions. 4 It is generally accepted that rhG-CSF treatment for PBSC collection has an excellent short-term safety profile but there are concerns for longterm safety. [5] [6] [7] Specifically, there are concerns for a potential risk of leukemic transformation. The only reported association of rhG-CSF with leukemia is in congenital neutropenia (Kostman syndrome) treated with rhG-CSF. 1 These patients often receive high doses of rhG-CSF for very prolonged period of time and many of them develop mutations in the G-CSF receptor. 8 Few hematological side effects of rhG-CSF have been reported. Slight anemia and thrombocytopenia are occasionally observed and may be related to the pheresis procedure. 7, 9, 10 Transient splenomegaly was also observed. 11 Campbell et al 12 reported the appearance of large multilobed hypersegmented neutrophils in cancer patients treated with melphalan and rhG-CSF. These cells had double DNA content as shown by Feulgen staining. Cells with similar morphology were also observed in rats treated with high dosage of rhG-CSF. 13 The purpose of the current study was to examine the effects of short treatment with rhG-CSF without any chemotherapy on the morphology and ploidy of peripheral white blood cells. Using a novel multiparametric cellscanning system that provides combined sensitive morphological, immunocytochemical and cytogenetic analysis on the same cells, 14, 15 we report the appearance of tetraploid myeloid cells in the peripheral blood of PBSC donors after treatment with rhG-CSF.
Material and methods
Study population: Five healthy donors and five patients with lymphoma in remission harvested for autologous peripheral stem cell transplantation were leukapheresed according to established pheresis procedures. All were treated with rhG-CSF (Neupogen, Roche) 5-10 mg/kg for 3-5 days prior to leukapheresis. None of the lymphoma patients had received chemotherapy in the month preceding the harvest. The peripheral blood specimens were collected on the day of the harvest. All donors signed informed consent.
Specimen processing and analysis: The Duett System (BioView Ltd. Rehovot, Israel) provides combined analysis of cells by morphology or immunocytochemistry, and fluorescence in situ hybridization (FISH). Up to three parameters can be tested on the same cell (eg morphology and two rounds of FISH with different probes).
Specimen preparation and processing have been described by us in detail before. 14 In short, about 300 000 white blood cells were cytospun onto glass slides. The slides were stained with May-Grunwald-Giemsa (MGG; Sigma, St Louis, MO, USA) or with immunostaining for CD34 (DAKO, class III clone BIRMA-K3). The stained slides were scanned by the hematological workstation and the coordinates and images of all cells were saved for future reference during the next phases of analysis. At least 100 000 cells were scanned in each case.
FISH was performed after removal of the MGG staining or the immunostaining, as previously reported in detail 14 using the LSI BCR/ABL ES dual-color translocation DNA probe kit , CEP 8 and CEP XY DNA probe kits (Vysis, Inc., Downers Grove, IL, USA). Removal of hybridized probes and second FISH were performed as described. 14 Combined analysis of morphology and FISH: The system enables observation of the fluorescence signals in specific cells using a Â 100 objective (a magnification of Â 1000) in parallel to the morphology of the same cells, which were previously scanned. When a target cell is identified, rhG-CSF-induced tetraploid C Kaplinsky et al the system saves its morphological and FISH images, as well as its coordinates. From now on, whenever the cell is presented, both the morphological and the FISH images are viewed simultaneously.
Results and discussion
Tetraploid cells were observed in the peripheral blood of eight out of 10 donors (Table 1) . Tetraploidy was detected by probes for sex chromosomes (Figure 1b, e) and was confirmed by a secondary FISH on the same cells with autosomal probes (Figure 1c, f, g ). Such cells have not been observed in individuals not treated with rhG-CSF (21 examinations of 15 individuals including eight adults and seven children, the number of cells examined in each time was 50 000-130 000). The frequency of these cells was low (average 0.26%, range 0.06-0.57%). There was no correlation between the frequency of tetraploid cells and the number of harvested CD34+ cells (data not shown).
Most of the tetraploid cells had the typical morphology of giant neutrophils or binucleated metamyelocytes (Figure 1a, d) . The least mature tetraploid cells observed were myelocytes (Table 1) . Consistent with this observation, the frequency of tetraploid cells in the pheresis product, enriched for mononuclear cells, was much lower (average 0.04%, range 0.002-0.057%) than in the donors' peripheral blood. To evaluate the ploidy of early progenitor cells, we performed combined immunostaining and FISH. All CD34+ cells were diploid ( Figure  2a, b) . Furthermore, no tetraploid cells were observed in the peripheral blood of 15 patients transplanted with peripheral stem cells and followed after engraftment. It seems likely, therefore, that the tetraploidy induced by a short exposure to rhG-CSF is limited to mature nonprogenitor cells.
G-CSF increases both proliferation and differentiation of myeloid progenitors. 16 The tetraploid cells observed appear because the nucleus divided but the cytoplasm did not. From their morphological appearance and degree of maturation, we speculate that the tetraploidy might have resulted from one skipped cell division in the promyelocyte stage. DNA replication, nuclear and cytoplasmic division are closely linked and strictly regulated. 17 For most cells (with rare exceptions such as in megakaryocytes) lack of completion of cell division results in apoptotic death. It is tempting to speculate that rhG-CSF therapy occasionally overrides this checkpoint control. In support of this speculation are recent reports that rhG-CSF induces antiapoptotic proteins in neutrophils and can rescue myeloid cells from apoptosis caused by treatment with DNA damaging agents. [18] [19] [20] Numerical chromosomal alterations induced by rhG-CSF therapy of PBSC donors raise concern for long-term safety. The low percentage of tetraploid cells and the lack of tetraploidy in CD34+ cells suggest that these genotypic alterations probably do not involve progenitor cells capable of leukemic transformation. However, assessment of a potential long-term risk requires prolonged observation of a large cohort of donors.
